Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop

Lalitha K Shankar; Heiko Schöder; Elad Sharon; Jedd Wolchok; Michael V Knopp; Richard L Wahl; Benjamin M Ellingson; Nathan C Hall; Martin J Yaffe; Alexander J Towbin; Michael D Farwell; Daniel Pryma; Tina Young Poussaint; Chadwick L Wright; Lawrence Schwartz; Mukesh Harisinghani; Umar Mahmood; Anna M Wu; David Leung; Elisabeth G E de Vries; Ying Tang; Gillian Beach; Steven A Reeves

doi:10.1016/S1470-2045(22)00742-2

Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop

Lancet Oncol. 2023 Mar;24(3):e133-e143. doi: 10.1016/S1470-2045(22)00742-2.

Authors

Lalitha K Shankar¹, Heiko Schöder², Elad Sharon³, Jedd Wolchok⁴, Michael V Knopp⁵, Richard L Wahl⁶, Benjamin M Ellingson⁷, Nathan C Hall⁸, Martin J Yaffe⁹, Alexander J Towbin¹⁰, Michael D Farwell⁸, Daniel Pryma⁸, Tina Young Poussaint¹¹, Chadwick L Wright⁵, Lawrence Schwartz¹², Mukesh Harisinghani¹³, Umar Mahmood¹³, Anna M Wu¹⁴, David Leung¹⁵, Elisabeth G E de Vries¹⁶, Ying Tang¹⁷, Gillian Beach¹⁸, Steven A Reeves¹⁹

Affiliations

¹ Clinical Trials Branch, National Cancer Institute, Rockville, MD, USA. Electronic address: [email protected].
² Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Investigational Drug Branch, National Cancer Institute, Rockville, MD, USA.
⁴ Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
⁵ Department of Radiology, Ohio State University, Columbus, OH, USA.
⁶ Department of Radiology, Washington University, St Louis, MO, USA.
⁷ Department of Radiological Sciences, University of California Los Angeles, Los Angeles, CA, USA.
⁸ Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA.
⁹ Medical Biophysics, University of Toronto, Toronto, ON, Canada.
¹⁰ Department of Radiology and Medical Imaging, Cincinnati Children's Hospital, Cincinnati, OH, USA.
¹¹ Department of Radiology, Boston Children's Hospital, Boston, MA, USA.
¹² Department of Radiology, Columbia University, New York, NY, USA.
¹³ Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.
¹⁴ Department of Immunology & Theranostics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
¹⁵ Bristol Myers Squibb, Princeton, NJ, USA.
¹⁶ Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands.
¹⁷ CCS Associates, McLean, VA, USA.
¹⁸ The Emmes Company, Rockville, MD, USA.
¹⁹ Coordinating Center for Clinical Trials, National Cancer Institute, Rockville, MD, USA.

Abstract

As the immuno-oncology field continues the rapid growth witnessed over the past decade, optimising patient outcomes requires an evolution in the current response-assessment guidelines for phase 2 and 3 immunotherapy clinical trials and clinical care. Additionally, investigational tools-including image analysis of standard-of-care scans (such as CT, magnetic resonance, and PET) with analytics, such as radiomics, functional magnetic resonance agents, and novel molecular-imaging PET agents-offer promising advancements for assessment of immunotherapy. To document current challenges and opportunities and identify next steps in immunotherapy diagnostic imaging, the National Cancer Institute Clinical Imaging Steering Committee convened a meeting with diverse representation among imaging experts and oncologists to generate a comprehensive review of the state of the field.

Publication types

Review

MeSH terms

Humans
Image Processing, Computer-Assisted
Immunotherapy
Medical Oncology
National Cancer Institute (U.S.)
Neoplasms*
United States

Abstract

Publication types

MeSH terms

Grants and funding